It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
While patient groups at risk for severe COVID-19 infections are now well identified, the risk factors associated with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission and immunization are still poorly understood. In a cohort of staff members of a Belgian tertiary academic hospital tested for SARS-CoV-2 antibodies during the early phase of the pandemic and followed-up after 6 weeks, 3 months and 10 months, we collected personal, occupational and medical data, as well as symptoms based on which we constructed a COVID-19 score. Seroprevalence was higher among participants in contact with patients or with COVID-19 confirmed subjects or, to a lesser extent, among those handling respiratory specimens, as well as among participants reporting an immunodeficiency or a previous or active hematological malignancy, and correlated with several symptoms. In multivariate analysis, variables associated with seropositivity were: contact with COVID-19 patients, immunodeficiency, previous or active hematological malignancy, anosmia, cough, nasal symptoms, myalgia, and fever. At 10 months, participants in contact with patients and those with higher initial COVID-19 scores were more likely to have sustained antibodies, whereas those with solid tumors or taking chronic medications were at higher risk to become seronegative.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 CHU Sart-Tilman, Division of Hematology, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
2 CHU of Liège, Division of Medical Microbiology, Unilab, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, Center for Interdisciplinary Research On Medicines, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
3 CHU of Liège, Biothèque Hospitalo-Universitaire de Liège (BHUL), Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
4 CHU of Liège, Department of Biostatistics and Medico-Economic Information, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
5 CHU of Liège, Unilab, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
6 CHU of Liège, Division of Infectious Diseases and General Internal Medicine, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, GIGA-I3 Laboratory of Immunology, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
7 CHU of Liège, Department of Information System Management, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, Department of Biomedical and Preclinical Sciences, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
8 CHU Sart-Tilman, Division of Hematology, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); CHU of Liège, Biothèque Hospitalo-Universitaire de Liège (BHUL), Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858); University of Liège, GIGA-I3 Laboratory of Hematology, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)